Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation with persistent respiratory symptoms.[@CIT0001] The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report places emphasis on the assessment of symptoms and exacerbation risk for newly diagnosed patients.[@CIT0001] These parameters enable patients to be categorized using an ABCD assessment, with specific initial pharmacological treatment recommendations defined for each group.[@CIT0001],[@CIT0002]

The evidence base for these initial treatment recommendations comes from randomized controlled trials (RCTs) that recruited patients already taking maintenance pharmacological treatment and included patients with more advanced disease. Whether the results of these clinical trials apply to newly diagnosed patients with COPD, who are not taking any treatment, is unclear.

RCTs of long-acting bronchodilators often allow patients who are using inhaled corticosteroids (ICS) currently to continue with these drugs. The concurrent use of ICS may influence the treatment effects observed.[@CIT0003] Furthermore, the use of maintenance long-acting bronchodilator(s) before the study may result in "step-down" effects being observed after randomization. Recommendations for the initial pharmacological management of newly diagnosed patients with COPD should ideally be based on evidence from patients who were not taking any maintenance treatment before the trial, to avoid step-down effects and/or the confounding effects of ICS use.

This paper aims to evaluate evidence from RCTs and non-interventional observational studies concerning the efficacy of pharmacological treatments in maintenance-naïve patients with COPD. We review studies that enrolled maintenance-naïve patients, and also any post-hoc analyses of this subgroup in RCTs. We also present a new pooled post-hoc subgroup analysis of data from maintenance-naïve patients with COPD in the ACLIFORM and AUGMENT studies of aclidinium bromide (AB)/formoterol fumarate (FF) (AB/FF).[@CIT0004],[@CIT0005] The results of these two studies have been reported previously, demonstrating the efficacy of AB/FF in improving bronchodilation and symptoms versus monotherapy or placebo and also reducing exacerbations versus placebo.[@CIT0004]--[@CIT0006] Here we analyze the same endpoints in the treatment-naïve patient subgroup, to assess the efficacy of AB/FF induced bronchodilation in this sub-population.

Materials And Methods {#S0002}
=====================

Search Strategy {#S0002-S2001}
---------------

To establish the existing evidence base, a literature review was performed to identify clinical studies that included analyses of maintenance therapy-naïve patients with COPD. Searches in PubMed were conducted for the terms "COPD" and "treatment-naïve/treatment naïve/naïve to maintenance therapy/naïve to maintenance treatment/maintenance-naïve/maintenance naïve/long-acting β~2~-agonist (LABA)-naïve/LABA naïve/long-acting muscarinic antagonist (LAMA)-naïve/LAMA naïve/prior treatment/prior therapy/inexperienced/first maintenance."

Further details of the search strategy are shown in [[Supplementary Figure 1](https://www.dovepress.com/get_supplementary_file.php?f=217710.docx)]{.ul}.

Maintenance-naïve was generally defined as naïve to the following maintenance treatments: LABA, LAMA, ICS, or systemic corticosteroids and xanthines. Some studies also excluded short-acting muscarinic antagonists, β~2~-agonists plus steroids, bronchodilator combinations, β~2~-agonists plus anticholinergic/short-acting muscarinic antagonists and leukotriene antagonists in the months preceding the study. Exclusive use of short-acting β~2~-agonists (SABA) was generally permitted prior to study inclusion.

Post-Hoc Analysis Of Patients In ACLIFORM And AUGMENT {#S0002-S2002}
-----------------------------------------------------

We performed a post-hoc subgroup analysis of maintenance therapy-naïve patients in two large phase III, randomized, double-blind, 24-week trials investigating the efficacy of AB/FF fixed-dose combination versus either monotherapy or placebo in patients with COPD (ACLIFORM \[NCT01462942\] and AUGMENT \[NCT01437397\]). The methods used in ACLIFORM and AUGMENT have been described previously.[@CIT0004],[@CIT0005] Briefly, patients with moderate-to-severe stable COPD were randomized to receive AB/FF 400/12 µg, AB/FF 400/6 µg, AB 400 µg, FF 12 µg, or placebo twice daily via a multidose dry powder inhaler (Genuair^TM^/Pressair^®^ \[the registered trademarks of the AstraZeneca group of companies; for use within the USA as Pressair^®^ and Genuair™ within all other licensed territories\]) for 24 weeks. In this pooled post-hoc analysis, treatment-naïve patients were defined as those patients who had not received prior maintenance therapy for COPD: i.e., any LABA, LAMA, ICS, or xanthines; short-acting bronchodilators were permitted. Patients enrolled in the studies were not specifically required to have an established duration of COPD. Prior and concomitant medication data were collected and defined at screening up to approximately 2 weeks prior to randomization, and during the run-in period, resulting in the collection of medication data for at least 4 weeks before the first dose of study medication. Of the two AB/FF arms, only the currently approved 400/12 µg dose[@CIT0007] is included here. Both the studies included in this post-hoc analysis were conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation/Good Clinical Practice Guidelines, and local regulations. The regulatory authorities approved the protocols for each country and each center had an independent ethics committee.

ACLIFORM And AUGMENT Post-Hoc Statistical Analysis {#S0002-S2003}
--------------------------------------------------

Full statistical information for ACLIFORM and AUGMENT has been described previously.[@CIT0004],[@CIT0005] The post-hoc analysis presented here included patients who were naïve to maintenance therapy from the pooled intent-to-treat (ITT) population (excluding those allocated to AB/FF 400/6 µg). Changes from baseline at Week 24 were analyzed for the following endpoints: pre-dose (trough) and 1 hr morning post-dose forced expiratory volume in 1 second (FEV~1;~ mL), Transition Dyspnea Index (TDI) focal score, and St George's Respiratory Questionnaire (SGRQ) total score. Changes from baseline in daily symptoms, as measured using the Evaluating-Respiratory Symptoms (E-RS™ \[the E-RS™ is owned by Evidera. Permission has been granted for this publication. Permission to use this instrument may be obtained from Evidera (<exactpro@evidera.com>)\]; formerly known as EXAcerbations of Chronic pulmonary disease Tool -- Respiratory Symptoms) total score,[@CIT0008] and morning and nighttime symptoms were analyzed over 24 weeks using the Nighttime Symptoms of COPD Instrument[@CIT0009],[@CIT0010] and Early Morning Symptoms of COPD Instrument tools.[@CIT0011] All reported data are least squares (LS) mean changes from baseline with 95% confidence intervals (CI), based on the mixed model for repeated measures: treatment effects and treatment comparisons. LS mean differences between AB/FF 400/12 µg and treatment groups are also shown (Δ). For changes from baseline in trough and morning post-dose FEV~1~, TDI, SGRQ, E-RS, nighttime and early morning outcomes, analyses were adjusted using the main common predictors i.e. screening response (FEV~1~, only), baseline scores and age as covariates, and any of the following criteria as fixed effect factors: treatment group, study, sex, smoking status, visit, prior naïve COPD patients, and interactions of treatment group-by-visit, treatment group-by-prior naïve COPD patients, and treatment group-by-visit-by-prior naïve COPD patients. Minimal clinically important difference (MCID) for each outcome: SGRQ (≥4-unit change),[@CIT0012] trough FEV~1~ (change of approximately 100 mL),[@CIT0013] TDI focal score (increase of 1 unit),[@CIT0014] and COPD Assessment Test (CAT) score  (2-point reduction),[@CIT0015] as previously published.

Results {#S0003}
=======

Treatment In Maintenance Therapy-Naïve Patients {#S0003-S2001}
-----------------------------------------------

The literature search identified nine relevant studies that showed clinical outcomes in a COPD maintenance therapy-naïve patient population or with a COPD maintenance therapy-naïve sub-population ([Table 1](#T0001){ref-type="table"}). Of the nine studies identified, two were dual bronchodilator RCTs, four were long-acting bronchodilator monotherapy RCTs, one was a real-world study of guidelines-based treatment, and two were non-interventional observational studies. All reported positive findings for the efficacy of LABA, LAMA, or LAMA/LABA treatment in maintenance therapy-naïve populations.[@CIT0016]--[@CIT0024] Six of the nine studies investigated the lung function effects of bronchodilators in treatment-naïve patients,[@CIT0016],[@CIT0018],[@CIT0020]--[@CIT0024] while all nine studies investigated symptoms and quality of life (QoL).[@CIT0016]--[@CIT0024]Table 1Studies Investigating The Efficacy Of Maintenance Treatments In Treatment-Naïve Patients With COPDStudyType Of Analysis/StudyNumber Of Maintenance-Therapy-Naïve PatientsDisease SeverityTreatmentsFinding**RCTs**Troosters et al *Eur Respir J*. 2010[@CIT0024]Pre-specified subgroup analysis of a 4-year RCT (UPLIFT^®^)N=810GOLD stage II = 60%; stage III = 34%; stage IV = 5%Tiotropium versus placeboImproved FEV~1~ and SGRQ total score versus placebo\
Reduced lung function declineVogelmeier et al *Respir Med*. 2013[@CIT0022]Pre-specified subgroup analysis of a 1-year RCT (POET-COPD^®^)N=1343GOLD stage II = 48--54%; stage III = 41--37%Tiotropium versus salmeterolReduced annual exacerbation rate versus salmeterolTroosters et al *NPJ Prim Care Resp Med*. 2014[@CIT0021]24-week RCTN=457GOLD stage II = 100%Tiotropium versus placeboImproved FEV~1~, Physician's Global Assessment, and WPAI questionnaireDecramer et al *Respir Med*. 2012[@CIT0023]Post-hoc subgroup analysis of pooled data from two 6-month RCTs and one 12-month RCTN=933GOLD stage I--II = 62--71%Indacaterol versus tiotropium and placeboIndacaterol improved trough FEV~1~, TDI, rescue use, and SGRQ vs placebo\
Tiotropium improved trough FEV~1~ and TDI total score vs placeboSingh et al *Respir Res*. 2016[@CIT0018]Post-hoc subgroup analysis of two 12-week RCTs (OTEMTO^®^ 1 and 2)N=678GOLD stage II--III = 100%Tiotropium + olodaterol versus tiotropium monotherapy or placeboImproved FEV~1~, SGRQ, and TDI vs monotherapy or placeboMaleki-Yazdi et al *Adv Ther*. 2017[@CIT0016]Post-hoc subgroup analysis of pooled data from three 24-week RCTsN=533GOLD stage II = 55--56%; stage III = 37--38%Umeclidinium + vilanterol versus tiotropiumImproved trough FEV~1~, rescue use, SGRQ and short-term clinically important deterioration vs tiotropium**Non-interventional studies**Setoguchi et al *Expert Opin Pharmacother*. 2015[@CIT0020]Real-world, observational multicenter survey over 48 weeksN=49GOLD stage I = 12.2%; stage II = 40.8%; stage III = 32.7%; stage IV = 10.2%Guideline-based pharmacotherapy^c^Improved CAT score and symptomsLange et al *Eur Clin Respir J*. 2016[@CIT0017]Observational multicenter study, over 24 weeksN=245^a^GOLD B = 56%; GOLD D = 25%Aclidinium (no comparator)Improved CAT score, the severity of morning and nighttime symptoms, and mMRC grade in LAMA-naïve patientsSauer et al *Int J Chron Obstruct Pulmon Dis*. 2016[@CIT0019]Observational, open-label study, over 4--6 weeksN=567^b^GOLD B = 55%; GOLD C = 32%; GOLD D = 9%Tiotropium + olodaterol (no comparator)Treatment-naïve patients had higher therapeutic success rates (10-point increase in PF-10) versus those with prior maintenance therapy[^1]

### Long-Acting Bronchodilator Monotherapy Studies {#S0003-S2001-S3001}

Four RCTs evaluated lung function, exacerbations, symptoms, and quality of life outcomes for treatment-naïve patients receiving monotherapy with either tiotropium[@CIT0021],[@CIT0022],[@CIT0024] or indacaterol.[@CIT0023] Tiotropium or indacaterol generally showed significant improvements in a range of lung function measurements versus placebo.[@CIT0021],[@CIT0023],[@CIT0024] Compared with placebo, the trough FEV~1~ improvements for indacaterol 150 µg and 300 µg were 170 mL and 180 mL, respectively, (*P*\<0.001) at 6 months ([Figure 1A](#F0001){ref-type="fig"}).[@CIT0023] In two RCTs of tiotropium versus placebo, the trough FEV~1~ improvements were 140 mL at Week 24[@CIT0021] and 134 mL after 4 years (both *P*\<0.001; [Figure 1A](#F0001){ref-type="fig"}).[@CIT0024]Figure 1Treatment differences in trough FEV~1~ for (**A**) monotherapies and (**B**) dual therapies among the relevant publications identified in the literature search.**Notes:** Data are least square means differences unless stated otherwise. P-values and 95% CI included where available. ^a^Mean difference. \*\*\**P*\<0.001 versus placebo. Panel B is reproduced from the original publication Singh et al 2016,[@CIT0018] with a simplification of the figure to include only maintenance treatment-naïve subgroups. Reproduced from Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies. *Respir Res*. 2016;17(1):73. Creative Commons license and disclaimer available from: [<http://creativecommons.org/licenses/by/4.0/>]{.ul} and [<http://creativecommons.org/publicdomain/zero/1.0/>]{.ul}.[@CIT0018]**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 second.

In treatment-naïve patients at 6 months, indacaterol 150 µg and 300 µg showed significant improvements (*P\<*0.001 and *P\<*0.05, respectively) versus placebo in symptoms and health status including SGRQ (treatment difference vs placebo for 150 µg and 300 µg of --6.1 and --2.5 units, respectively; *P*\<0.001 and *P*\<0.05, respectively; [Figure 2A](#F0002){ref-type="fig"}), rescue use (--0.48 and --0.59 puffs/day; *P*\<0.01), and TDI total score (1.27 and 1.04 points; *P*\<0.001).[@CIT0023] Tiotropium also significantly improved SGRQ versus placebo (treatment difference --4.57 units at 48 months; 95% CI --7.06 to --2.09) ([Figure 2A](#F0002){ref-type="fig"}).[@CIT0024]Figure 2Changes in SGRQ total score for (**A**) monotherapies and (**B**) dual therapies; (**C**) changes in TDI focal score for dual therapies, among the relevant publications identified in the literature search.**Notes:** ^a^SGRQ total units. \**P*\<0.05; \*\*\**P* \<0.001 versus placebo. Panels B and C are reproduced from the original publication Singh et al 2016,[@CIT0018] with the simplification of the figure to include only maintenance treatment-naïve subgroups. Reproduced from Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies. *Respir Res*. 2016;17(1):73. Creative Commons license and disclaimer available from: [<http://creativecommons.org/licenses/by/4.0/>]{.ul} and [<http://creativecommons.org/publicdomain/zero/1.0/>]{.ul}.[@CIT0018]**Abbreviations:** CI, confidence interval; SGRQ, St George's Respiratory Questionnaire; TDI, Transition Dyspnea Index.

There is currently little information available on the exacerbation risk in treatment-naïve patients; however, in one of two analyses of maintenance therapy-naïve patients, tiotropium significantly increased time to first exacerbation (*P*\<0.05), and reduced annual rates of exacerbations (*P*\<0.05) versus salmeterol,[@CIT0022] and the other analyses showed a numerically decreased exacerbation rate by 16% (*P*\<0.08; non-significant) versus placebo.[@CIT0024]

One study evaluated a decline in lung function over 4 years and showed that tiotropium slowed annual decline compared with placebo (post-bronchodilator FEV~1~ tiotropium 42 mL/year vs placebo 53 mL/year; *P*\<0.05).[@CIT0024] There was also a slowed decline in the activity domain of SGRQ (difference 1.44±0.40 units; *P\<*0.001; total score difference 4.6 units; *P\<*0.001) with tiotropium versus placebo over 4 years.[@CIT0024]

### Dual Bronchodilator Studies {#S0003-S2001-S3002}

Two studies presented dual bronchodilator outcomes for maintenance therapy-naïve patients as post-hoc analyses.[@CIT0016],[@CIT0018] Dual bronchodilation with LAMA/LABA combinations umeclidinium/vilanterol[@CIT0016] or tiotropium/olodaterol[@CIT0018] provided greater improvements in lung function and health status compared with monotherapy in treatment-naïve patients. Umeclidinium/vilanterol dual bronchodilation showed a significant 146 mL improvement (*P\<*0.001) from baseline in trough FEV~1~ versus tiotropium monotherapy at Day 169 ([Figure 1A](#F0001){ref-type="fig"}).[@CIT0016] Similarly, dual therapy with tiotropium/olodaterol showed improvements in both trough and post-dose FEV~1~ versus placebo and improvements for post-dose FEV~1~ versus tiotropium monotherapy, only. For trough FEV~1,~ tiotropium/olodaterol versus tiotropium monotherapy showed 95% CIs crossing zero, indicating no significant difference between treatments ([Figure 1B](#F0001){ref-type="fig"}).[@CIT0018]

In terms of QoL, both umeclidinium/vilanterol and tiotropium/olodaterol improved total SGRQ scores from baseline over 12 or 24 weeks (≥4-unit decrease),[@CIT0012] with both dual therapies resulting in greater improvements compared with tiotropium monotherapy (and also vs placebo for tiotropium/olodaterol).[@CIT0016],[@CIT0018] The effect size of improvement versus tiotropium monotherapy was approximately --2 units for both umeclidinium/vilanterol[@CIT0016] and tiotropium/olodaterol ([Figure 2B](#F0002){ref-type="fig"}), less than the recognized MCID for SGRQ (≥4-unit change).[@CIT0018]

Symptom measures were reported in one study of tiotropium/olodaterol dual therapy, which showed that TDI focal score was improved versus tiotropium monotherapy with an effect size of approximately 0.5 units at 12 weeks ([Figure 2C](#F0002){ref-type="fig"}).[@CIT0018] Umeclidinium/vilanterol showed significantly greater proportions (47%) of patients achieving an increase in clinically meaningful rescue-free periods (one extra rescue-free month per year or two extra rescue-free weeks out of 24) versus tiotropium monotherapy (37%; odds ratio \[OR\]: 1.5 \[95% CI: 1.0--2.2\]).[@CIT0016]

### Non-Interventional Studies {#S0003-S2001-S3003}

There were three non-interventional, observational studies of bronchodilator therapy in treatment-naïve patients.[@CIT0017],[@CIT0019],[@CIT0020] An open-label, multicenter, observational, real-world survey confirmed that initiation of Japanese guideline[@CIT0025]-directed bronchodilator therapy in Japanese patients with untreated COPD resulted in improved lung function.[@CIT0020] GOLD COPD stage I patients received single LAMA, GOLD stage II and III patients received LAMA plus one other of the following additional therapies: LABA, theophylline or ICS/LABA; GOLD stage IV patients received LAMA plus two of the additional therapies. There were also clinically important differences (2-point reduction)[@CIT0015] in mean CAT scores, with improvements from 14.2 at Week 0 to 12.3 at Week 48 (*P*=0.022).[@CIT0020]

In a Nordic population of patients with COPD, aclidinium monotherapy in LAMA-naïve patients without concomitant maintenance therapy showed significant improvements from baseline in CAT total score (--3.8 mean change \[95% CI --4.6 to --3.1\]; *P\<*0.05) and exceeded the MCID. There were also improvements from baseline in both morning and nighttime symptoms (both *P\<*0.01).[@CIT0017] For LAMA-naïve patients adding aclidinium to existing maintenance therapy, there were significant improvements from baseline for outcomes including CAT (--3.3; *P\<*0.05), modified Medical Research Council  Dyspnea Scale (--0.3), and morning and nighttime symptoms (all *P\<*0.01).[@CIT0017]

An observational study in patients with COPD receiving dual therapy with tiotropium/olodaterol found that treatment-naïve patients had a higher therapeutic success rate (defined as a 10-point increase in the Physical Functioning Questionnaire between baseline and Weeks 4--6) than those with prior maintenance therapy (59.1% vs 44.5%; *P\<*0.0001). These differences were driven by a higher response in treatment-naïve patients who were classified as GOLD B (59.8%) and C (63.0%); whereas proportions of patients achieving therapeutic success were similar for GOLD D patients, regardless of previous maintenance treatment history.[@CIT0019]

Efficacy Of AB/FF In Maintenance-Therapy-Naïve Patients: A Post-Hoc Analysis Of Patients In ACLIFORM And AUGMENT {#S0003-S2002}
----------------------------------------------------------------------------------------------------------------

Of 3421 patients in the pooled study population, 3394 were included in the pooled ITT population, and 1056 were naïve to maintenance therapy and included in this analysis (excluding those allocated to AB/FF 400/6 µg).

Patient demographics and baseline characteristics of treatment-naïve patients were similar across treatment groups ([Table 2](#T0002){ref-type="table"}). Compared with treatment-exposed patients, treatment-naïve patients were younger, more likely to be current smokers, had higher baseline FEV~1~ and similar reversibility ([Table 2](#T0002){ref-type="table"}). Treatment-naïve patients had moderately lower rates of prior year exacerbations, lower oxygen, and oral corticosteroid use, and lower E-RS scores at baseline. North American patients were more likely to be treatment-naïve (62.8% vs 38.9% non-naïve), whereas European patients were more likely to have received prior maintenance therapy (53.1% vs 31.2% naïve).Table 2Patient Demographics And Baseline Characteristics Of Patients Included In ACLIFORM And AUGMENT (Post-Hoc Analysis; ITT Population)Treatment-NaïveAll Treatment-Naïve^a^All Treatment-Exposed^a^AB/FF\
400/12 µgAB\
400 µgFF\
12 µgPlaceboN=282N=272N=278N=224N=1339N=2055Age, years, mean (SD)61.9 (8.8)62.7 (8.9)62.3 (8.8)61.6 (8.8)62.0 (8.8)64.5 (8.1)Male, n (%)161 (57.1)174 (64.0)168 (60.4)137 (61.2)818 (61.1)1235 (60.1)White, n (%)256 (90.8)253 (93.0)256 (92.1)211 (94.2)1239 (92.5)1954 (95.1)Current smoker, n (%)175 (62.1)156 (57.4)162 (58.3)130 (58.0)804 (60.0)872 (42.4) Pack-years, mean (SD)46.5 (23.9)47.0 (25.8)47.5 (22.2)50.0 (25.5)47.7 (24.5)45.5 (24.2)Baseline GOLD I0 (0.0)1 (0.4)0 (0.0)0 (0.0)2 (0.1)3 (0.1) II188 (66.9)173 (63.8)189 (68.0)127 (56.7)867 (64.8)1120 (54.6) III92 (32.7)96 (35.4)86 (30.9)95 (42.4)460 (34.4)922 (45.0) IV1 (0.4)1 (0.4)3 (1.1)2 (0.9)8 (0.6)6 (0.3)Number of exacerbations in previous 12 months, mean (SD)0.4 (0.7)0.4 (0.8)0.3 (0.7)0.3 (0.6)0.3 (0.7)0.5 (0.9)Baseline FEV~1~, L, mean (SD)1.536 (0.560)1.478 (0.541)1.513 (0.513)1.471 (0.611)1.512 (0.556)1.312 (0.486)N=282N=271N=278N=223N=1337N=2055Baseline FEV~1~, % predicted, mean (SD)52.3 (14.5)49.8 (14.3)51.6 (14.4)48.0 (14.9)50.8 (14.5)46.8 (13.7)N=280N=270N=278N=224N=1335N=2049Reversibility, %, mean (SD)12.9 (13.3)15.8 (17.0)13.7 (12.9)16.2 (16.0)14.6 (14.8)15.7 (14.4)N=273N=264N=271N=219N=1299N=1998BDI focal score, mean (SD)6.6 (2.0)6.6 (2.1)6.6 (2.3)6.6 (2.2)6.6 (2.2)6.4 (2.1)N=280N=270N=275N=219N=1318N=2018Baseline E-RS total score, mean (SD)11.8 (6.0)12.0 (6.2)11.9 (6.6)11.5 (6.1)11.8 (6.3)13.1 (6.6)N=280N=270N=273N=219N=1316N=2023Baseline early-morning COPD symptom severity score, mean (SD)1.2 (0.6)1.2 (0.6)1.2 (0.7)1.1 (0.6)1.2 (0.6)1.3 (0.7)Baseline overall nighttime COPD symptom severity score, mean (SD)1.1 (0.6)1.1 (0.7)1.1 (0.7)1.0 (0.7)1.1 (0.7)1.1 (0.7)N=276N=264N=275N=221N=1315N=2009Baseline total SGRQ, mean (SD)47.2 (17.8)45.7 (16.9)45.9 (18.5)45.4 (17.9)46.0 (17.9)46.2 (17.5)N=282N=272N=278N=224N=1339N=2055Any prior treatment, n (%)138 (48.9)143 (52.6)137 (49.3)110 (49.1)671 (50.1)2055 (100.0) SABA115 (40.8)109 (40.1)111 (39.9)94 (42.0)549 (41.0)1185 (57.7) SAMA9 (3.2)14 (5.1)9 (3.2)8 (3.6)52 (3.9)148 (7.2) SABA+SAMA24 (8.5)29 (10.7)24 (8.6)19 (8.5)125 (9.3)188 (9.1) LABA0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)378 (18.4) LAMA0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)909 (44.2) LABA+ICS0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1059 (51.5) ICS0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)478 (23.3) Xanthines0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)255 (12.4) Leukotriene modifiers0 (0.0)2 (0.7)1 (0.4)1 (0.4)4 (0.3)41 (2.0) Oxygen4 (1.4)2 (0.7)9 (3.2)6 (2.7)26 (1.9)61 (3.0) Influenza vaccine0 (0)4 (1.5)4 (1.4)0 (0)9 (0.7)26 (1.3) Systemic corticosteroid2 (0.7)2 (0.7)1 (0.4)3 (1.3)9 (0.7)24 (1.2)[^2][^3]

At Week 24, patients receiving AB/FF showed significant improvements from baseline in 1 hr post-dose FEV~1~ ([Figure 3A](#F0003){ref-type="fig"}), versus AB, FF, and placebo (LS mean difference 84 mL, 117 mL, and 284 mL, respectively; all *P\<*0.001). AB/FF also showed significantly greater improvement from baseline in trough FEV~1~ versus FF (57 mL; *P\<*0.01) and placebo (134 mL; *P* \<0.001) ([Figure 3B](#F0003){ref-type="fig"}), although there was no significant difference between AB/FF and AB (14 mL; *P*=0.484). Patients receiving AB/FF also had significantly improved changes from baseline in TDI focal scores compared with AB (1.17; *P\<*0.001), FF (0.92; *P\<*0.01), and placebo (1.54; *P\<*0.001) at Week 24 ([Figure 4A](#F0004){ref-type="fig"}).Figure 3Change from baseline in (**A**) 1 hr morning post-dose FEV~1~ and (**B**) trough FEV~1~ for treatment-naïve patients, at Week 24 of ACLIFORM and AUGMENT (post-hoc analysis; ITT population).**Notes:** \*\**P\<*0.01; \*\*\**P\<*0.001. All data are LS mean changes from baseline. Analyses are based on the mixed model for repeated measures: treatment effects and treatment comparisons. LS mean differences between AB/FF 400/12 µg and treatment groups are shown (Δ).**Abbreviations:** AB, aclidinium bromide; CI, confidence interval; FEV~1~, forced expiratory volume in 1 sec; FF, formoterol fumarate; ITT, intent-to-treat; LS, least squares.Figure 4Patient-reported outcomes changes from baseline for treatment-naïve patients (**A**) TDI focal score at Week 24, (**B**) E-RS total score, (**C**) early morning COPD symptom severity and (**D**) nighttime COPD symptom severity over 24 weeks of ACLIFORM and AUGMENT (post-hoc analysis; ITT population).**Notes:** \**P\<*0.05; \*\**P\<*0.01; \*\*\**P\<*0.001. All data are LS mean changes from baseline. Analyses are based on the mixed model for repeated measures: treatment effects and treatment comparisons. LS mean differences between AB/FF 400/12 µg and treatment groups are shown (Δ).**Abbreviations:** AB, aclidinium bromide; CI, confidence interval; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating-Respiratory Symptoms; FF, formoterol fumarate; LS, least squares; TDI, Transition Dyspnea Index.

Change from baseline in E-RS total score was significantly greater with AB/FF compared with all other treatments over 24 weeks (--0.82 and --0.83 vs AB and FF, both *P\<*0.05; --1.45 vs placebo, *P\<*0.001; [Figure 4B](#F0004){ref-type="fig"}). Overall early morning symptom severity was significantly improved from baseline with AB/FF compared with AB (--0.09; *P\<*0.05; [Figure 4C](#F0004){ref-type="fig"}) and placebo (--0.13; *P\<*0.001); the improvement versus FF did not reach statistical significance (--0.04; *P=*0.317). Similarly, overall nighttime symptom severity was significantly improved from baseline with AB/FF compared with AB (--0.12; *P\<*0.01; [Figure 4D](#F0004){ref-type="fig"}), and placebo (--0.14; *P\<*0.001); and numerically improved versus FF (--0.05; *P=*0.20; non-significant). It is important to note that there was a relatively large placebo response observed for TDI focal score, E-RS total score, early morning- and nighttime- symptoms.

Additionally, there were significant improvements from baseline for SGRQ total score at Week 24, for AB/FF versus placebo (--5.3; *P\<*0.001), AB (--3.1; P\<0.01), and FF (--2.3; *P*\<0.05) ([Figure 5](#F0005){ref-type="fig"}). While all active treatment groups exceeded MCID versus baseline, only AB/FF (--5.3) exceeded the MCID versus placebo (≥4-unit decrease).[@CIT0012]Figure 5Changes from baseline for SGRQ total score for treatment-naïve patients, at Week 24 of ACLIFORM and AUGMENT (post-hoc analysis; ITT population).**Notes:** \**P\<*0.05; \*\**P\<*0.01; \*\*\**P\<*0.001. All data are LS mean changes from baseline. LS mean differences between AB/FF 400/12 µg and treatment groups are shown (Δ). The analysis was based on a mixed model for repeated measures: treatment effects and treatment comparisons.**Abbreviations:** AB, aclidinium bromide; CI, confidence interval; FF, formoterol fumarate; ITT, intent to treat; SGRQ, St George's Respiratory Questionnaire.

Discussion {#S0004}
==========

A review of the literature revealed several RCTs that included subgroups of treatment-naïve patients. Long-acting bronchodilator monotherapies and dual bronchodilator combinations both showed evidence of significant benefits on lung function, symptoms, and QoL. There was also evidence that LAMA monotherapy appeared to slow the course of FEV~1~ decline in treatment-naïve patients with COPD, who were mostly GOLD stage II and III.[@CIT0024] Furthermore, LAMA/LABA dual bronchodilator therapy provided additional benefits over monotherapy in maintenance therapy-naïve patients.[@CIT0016],[@CIT0018] Overall, these data combined with the new post-hoc analysis, support the case for using LAMA/LABA treatments as first-line therapy in COPD.

In general, in terms of lung function, the new post-hoc analysis of the effects of AB/FF in maintenance therapy-naïve patients demonstrated significantly greater benefits than LAMA or LABA mono-bronchodilator therapy. Compared with AB/FF, neither LAMA nor LABA monotherapy treatment was observed to provide similar levels of improvement for airflow ([Figure 3](#F0003){ref-type="fig"}) or symptom endpoints ([Figure 4](#F0004){ref-type="fig"}). Therefore, these maintenance therapy-naïve patients in ACLIFORM and AUGMENT appeared to benefit most from initial dual bronchodilation with AB/FF, which provided a combination of anticholinergic and sympathomimetic mechanisms to improve their COPD.

Furthermore, at Week 24, the improvement with AB/FF versus placebo in trough FEV~1~ (134 mL) exceeded the MCID (100 mL).[@CIT0013] AB/FF also improved patient-reported outcomes in these maintenance therapy-naïve patients to a greater extent than either of the monotherapies. At Week 24, patients receiving AB/FF had significantly improved TDI focal scores compared with monotherapies and placebo, with the improvement versus monotherapies approximately equal to the MCID (1 unit); the treatment differences versus AB and FF were 1.17 and 0.92, respectively.[@CIT0014],[@CIT0026] Other symptom and QoL analyses showed a similar pattern of results, supporting a greater effect of AB/FF versus monotherapies. These new data support the case that LAMA/LABA combinations can have a greater effect than long-acting bronchodilator monotherapies when used as initial treatment. GOLD recommends that initial treatment with LAMA/LABA should be reserved for individuals with a higher symptom burden.[@CIT0002] However, there is a lack of evidence identifying the clinical characteristics that could help identify which patients are most likely to benefit from initial treatment with dual bronchodilators; this topic needs further investigation in terms of prospective studies.

A retrospective database analysis in the UK investigated real-life prescribing of first maintenance therapy in COPD from 2009--2012, and observed that the most frequent first prescription was for LAMA (40.2%), followed by ICS+LABA (29.1%), and ICS monotherapy (15.5%); only 0.4% of patients had a first prescription of LAMA+LABA.[@CIT0027] However, this was before the introduction of LAMA/LABA combinations in a single inhaler. Additionally, 47.9% of patients initially assessed as GOLD group A and 49.0% of patients assessed as GOLD group B received an initial prescription of an ICS alone, or in combination with a bronchodilator.[@CIT0027] This illustrates the frequent use of ICS/LABA as an initial COPD prescription. A recent observational study of COPD exacerbation risk with LAMA versus LABA/ICS found that LABA/ICS was more effective than LAMA in patients with high blood eosinophil concentrations (\>4%) or counts (\>300 cells per μL) and also potentially for patients with more frequent exacerbations.[@CIT0028] LAMA and LABA/ICS showed similar effectiveness among patients with eosinophil concentrations \<4%, but the elevated pneumonia risk associated with the ICS component of LABA/ICS indicates that initiation with LAMA is more appropriate for patients with low eosinophil counts; although, it should be noted this analysis did not stratify patients by COPD severity or eosinophil count.[@CIT0028]

One study of dual tiotropium and olodaterol therapy showed that effect sizes for trough FEV~1~ and FEV~1~ area under the curve from 0--3 hrs were modestly higher for maintenance therapy-treated versus maintenance therapy-naïve patients, but the magnitude of effect of SGRQ total score and TDI focal improvements were similar irrespective of treatment history.[@CIT0018] The practical argument in favor of earlier intervention with dual bronchodilator therapy, as opposed to initiating treatment with monotherapy and later escalating to dual therapy, is that it enables an earlier reduction in the overall disease burden, and could potentially reduce the risk or rate of disease progression in some patients.[@CIT0004],[@CIT0016],[@CIT0029] Furthermore, early intervention in COPD may benefit patients as they can maintain levels of activity.[@CIT0030]

A limitation of the existing evidence for efficacy of maintenance therapy in treatment-naïve patients is that patients included in the studies identified here had a wide range of disease severity from mild to very severe, suggesting that although these patients are receiving treatment for the first time, they may have been living with undiagnosed COPD for a considerable period. This precludes definitive comparison between studies. Additionally, the possibility of a publication bias exists, wherein studies showing significant results may be more likely to be published and therefore identified in our search. As with most of the other studies, our analysis was post-hoc and used a specific definition of maintenance therapy-naïve (≥4 weeks of no use of maintenance COPD medications). As such, at least some patients may have used maintenance treatments in the past, which although not received at the time of the current studies, meant there was a possibility of carry-over effects from prior treatments being observed in these studies. Additionally, our maintenance therapy-naïve patients were younger, with higher FEV~1~, and higher levels of current smoking than maintenance therapy-treated patients. These baseline differences might suggest the maintenance therapy-naïve group may be at an earlier, less severe stage of COPD than those already receiving maintenance therapy. There is a need for more prospective studies in patients diagnosed earlier and with milder COPD to evaluate the benefits of introducing maintenance therapy, including dual bronchodilator therapy, at an earlier stage in the development of COPD.

Conclusions {#S0005}
===========

The findings presented here from retrospective analysis in treatment-naïve patients with COPD, demonstrate the effectiveness of various therapeutic interventions in this population. Of importance, intervention with dual bronchodilator therapy, such as AB/FF, as a first COPD maintenance treatment may provide greater benefits than LAMA or LABA monotherapy.
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[^1]: **Notes:** ^a^LAMA-naïve patients, only. In this study, there was also an additional separate subgroup of 172 patients naïve to LAMA but receiving other maintenance therapies. ^b^Maintenance therapy-naïve patients, only. In total for this study, there were 1858 patients with/without prior maintenance therapy. ^c^GOLD COPD stage I patients received single LAMA; GOLD stage II and III patients received LAMA plus one other of the following additional therapies: LABA, theophylline or ICS/LABA; GOLD stage IV patients received LAMA plus two of the additional therapies. A total of 205 results were identified by the search terms stated; only relevant, original studies showing clinical outcomes in a COPD maintenance therapy-naïve patient population or with a COPD maintenance therapy-naïve sub-population, are shown. Maintenance therapy-naïve was generally defined as naïve to the following maintenance medications: LABA, LAMA, ICS, or systemic corticosteroids and xanthines. Some studies also excluded short-acting muscarinic antagonists and leukotriene antagonists in the months preceding the study. Exclusive use of SABA was generally permitted prior to study inclusion.

    **Abbreviations:** CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; POET-COPD^®^, Prevention Of Exacerbations with Tiotropium in COPD; PF-10, 10-item Physical Functioning Questionnaire; RCT, randomized controlled trial; SABA, short-acting β~2~-agonist; SGRQ, St George's Respiratory Questionnaire; TDI, Transition Dyspnea Index; WPAI, work productivity and activity impairment.

[^2]: **Notes:** ^a^Includes patients allocated to AB/FF 400/6 µg (not shown). Treatment-naïve patients were defined as patients who had not received prior maintenance therapy for COPD; short-acting bronchodilators were permitted.

[^3]: **Abbreviations:** AB, aclidinium bromide; BDI, Baseline Dyspnea Index; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating-Respiratory Symptoms; FEV~1~, forced expiratory volume in 1 second; FF, formoterol fumarate; ITT, intent-to-treat; SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation.
